Popular weight-loss drugs Ozempic and Wegovy may slow biological aging
A clinical trial published in Nature Communications indicates that the weight-loss drug semaglutide may help slow biological aging markers in adults living with HIV. Researchers observed that participants using the medication showed improvements in epigenetic clocks compared to those on a placebo.
The growing popularity of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus has largely been driven by their ability to help people lose weight, improve blood sugar control, and reduce the risk of cardiovascular disease. Now, researchers have uncovered another possible benefit. A new clinical trial suggests that semaglutide, the active ingredient in those medications, may also help slow some of the biological processes associated with aging.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in